DNA demethylating agents are approved for some blood malignancies and are under active investigation in solid tumors, but how these drugs work has remained unclear. In this issue of Cell, two groups show that these agents activate a toxic cellular antiviral program through transcriptional activation of endogenous retroviral sequences.
DNA methylation on cytosine residues at regulatory elements represents a critical layer of control of gene expression for processes such as X inactivation, imprinting, and differentiation. Methylated cytosines recruit protein complexes that promote functionally inert heterochromatin.
Studies dating back decades showed that cancer cells have a global decrease in DNA methylation, but at specific genes, DNA methylation is increased in association with silencing of genes that control cell growth, often including tumor suppressors (Timp and Feinberg, 2013) . Aberrant DNA methylation patterns have been hypothesized to allow cells to sample novel states of DNA methylation and gene expression, some of which may stimulate the initiation or progression of malignancy. This model posits that removal of the aberrant DNA methyl mark by agents such as 5-azacitidine (AZA) and decitabine (DEC) will inhibit tumor cells by reactivation of silenced tumor suppressor programs and potentially synergize with conventional therapies. However, the effects of demethylating agents are diverse, and identification of genes whose reactivation predicts or mediates response has been elusive. Furthermore, low-dose AZA or DEC treatment can induce long-lasting decreases in self-renewal and tumorigencity of tumor-initiating cells without cytotoxicity or changes in cell cycle, as predicted by acute reactivation of tumor suppressors (Tsai et al., 2012) . This correlates with the slow onset of therapeutic responses to demethylating agents in acute myeloid leukemia and myelodysplasia and persistence of response after therapy ends. In this issue of Cell, new data from two groups, Roulois et al. and Chiappinelli et al., indicate that demethylating agents can induce a cell-autonomous immune activation response by stimulating expression of endogenous retroviruses. This anti-viral response may underlie some of the anti-tumor activity of these drugs.
A link between demethylating agents and the immune system was made over a decade ago in experiments that showed that AZA could demethylate and activate genes encoding MHC class I genes and tumor antigens (Karpf et al., 1999 (Karpf et al., , 2004 . Interferon pathway genes were also upregulated by AZA, and this was correlated with increased expression of endogenous retroviral transcripts rather than de-repression of interferon pathway transcription factors. More recently it was shown that among the most common set of genes induced by AZA in solid tumor cell lines were those involved in antigen presentation and interferon response (Li et al., 2014) . This finding was corroborated by the observation that patients who had previously received AZA for lung cancer subsequently had a response to immune checkpoint inhibitors (Wrangle et al., 2013) .
In Roulois et al. (2015) , gene expression profiling of colorectal and ovarian carcinoma cells treated with low-dose AZA identified genes upregulated with delayed kinetics whose expression was not correlated with changes in DNA methylation, many of which were targets of the IRF7 protein, a known antiviral mediator. Probing upstream, these investigators found that AZA induced nuclear localization of IRF7 by stimulation of the MDA5 and RIG-I proteins that recognize double stranded viral RNA (Figure 1) . The anti-proliferative response to AZA depended on the RIG-I/MDA5 RNA response pathway, and moreover, double-stranded RNA (dsRNA) itself mimicked the effect of AZA in inhibiting self-renewal of colorectal cells. Chiappinelli et al. (2015) found that colon cancer cells treated with AZA actually began to secrete interferon, but this was not linked to demethylation of interferon pathway genes. Again, the evidence pointed to activation of endogenous retroviral sequences, as transfection of a fresh culture of cells with dsRNA derived from AZA-treated cells, but not control cells, induced an antiviral response in recipient cells.
These studies highlight another mode of action of demethylating agents in cancer and suggest new rational approaches to the use of such agents in immunotherapy. Indeed, Chiappinelli et al. provide evidence that inhibition of DNA methylation could sensitize a murine model of melanoma to anti-CTLA4 immune checkpoint therapy. Interferon itself has a limited role in cancer therapy, so why would AZA and as an indirect activator of cell autonomous antiviral immunity offer a benefit? The multi-faceted effects of demethylating agents might promote their potency by simultaneously inducing an antiviral, anti-proliferative state, reactivating tumor antigen expression and altering cell signaling pathways and apoptotic thresholds. Patients with low expression of MHC genes, low activity of antiviral pathways, and with a high tumor mutation burden that can create neoantigens might be the best candidates for the use of AZA in combination with antibodies directed against immune checkpoint regulators. These ideas are being tested in a clinical trial of anti-PD1 following a demethylating agent in lung cancer (NCT01928576). It will be critical to perform prospective immune monitoring in patients treated with demethylating agents, particular in light of the fact that Wrangle et al. (2013) showed that, in addition to increasing expression of tumor antigens, AZA can increase expression of the immunosuppressive PDL1. Furthermore, AZA promoted the development of immunosuppressive Treg cells in vitro and in patients (Stü big et al., 2014) .
The findings from Roulois et al. and Chiapellini et al. should propel new studies to determine how AZA and DEC work in myeloid malignancy, where their mode of action remains obscure. For example, one study of the combination of AZA with a histone deacetylase inhibitor showed that the most reliable marker of response was evidence of increased DNA damage (Fandy et al., 2009) , and the tumor suppressor reactivation model has yet to be proven in leukemia or any other malignancy. Whether the immune systems and retrovirus activation play any role in the activity of AZA and DEC in myeloid malignancy seems worth investigating. Lastly, given these new data, monitoring treated patients for the activation of retroviral transposable elements that could cause further damage to the cancer genome should be considered. DNA demethylating agents allow bidirectional transcription from endogenous retroviral sequences driven by the long terminal repeat (LTR) sequences, which are usually heavily methylated and inactivated. Proteins such as RIG-I and MDA5 sense the presence of dsRNA and interact with the MAVS anti-viral response protein at the mitochondria. MAVS mediates activation of IRF7 and induction of an antiviral state, including the secretion of interferon, which in turn contributes to reduced cell proliferation.
